Analyst Ratings For ACOR – Acorda Therapeutics (NASDAQ:ACOR)
Today, HC Wainwright reiterated its Buy rating on ACOR – Acorda Therapeutics (NASDAQ:ACOR) with a price target of $31.00.
Some recent analyst ratings include
- 4/2/2018-HC Wainwright Reiterated Rating of Buy.
- 3/21/2018-Oppenheimer Reiterated Rating of Hold.
- 2/15/2018-Piper Jaffray Upgrade from a “Neutral ” rating to a ” Overweight” rating.
- 2/7/2018-Goldman Sachs Upgrade from a “Sell ” rating to a ” Neutral” rating.
- 1/9/2018-JPMorgan Chase Reiterated Rating of Hold.
- 11/17/2017-Cowen Reiterated Rating of Buy.
- On 1/19/2018 David Lawrence, Insider, sold 31,000 with an average share price of $27.58 per share and the total transaction amounting to $854,980.00.
- On 12/1/2017 Burkhard Blank, Insider, sold 11,050 with an average share price of $20.53 per share and the total transaction amounting to $226,856.50.
- On 10/9/2017 David Lawrence, Insider, sold 250 with an average share price of $25.40 per share and the total transaction amounting to $6,350.00.
- On 8/29/2017 Scopia Capital Management Lp, Major Shareholder, bought 766,201 with an average share price of $19.23 per share and the total transaction amounting to $14,734,045.23.
- On 8/1/2017 Barry E Greene, Director, sold 10,000 with an average share price of $21.57 per share and the total transaction amounting to $215,700.00.
- On 7/31/2017 Lorin Randall, Director, sold 10,000 with an average share price of $21.66 per share and the total transaction amounting to $216,600.00.
- On 6/16/2017 Ron Cohen, Insider, bought 20,000 with an average share price of $16.95 per share and the total transaction amounting to $339,000.00.
Recent Trading Activity for ACOR – Acorda Therapeutics (NASDAQ:ACOR)
Shares of ACOR – Acorda Therapeutics closed the previous trading session at with 22.950000762939453 shares trading hands.